Results 251 to 260 of about 2,758,483 (364)

Gender Aspects of “Subjectivity” in the Private and Public Spheres: Sociological Analysis

open access: diamond, 2016
С. А. Ильиных   +4 more
openalex   +2 more sources

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Pulsed Field Ablation-Related Hemolysis: Comparison Between Technologies. [PDF]

open access: yesCirc Arrhythm Electrophysiol
Gianni C   +14 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

open access: yesMolecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal   +4 more
wiley   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Image reconstruction and elongation artifact reduction for a dual-panel dedicated prostate PET scanner. [PDF]

open access: yesMed Phys
Saberi Manesh A   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy